Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Cancer cells

Cancer & RA Drugs: Are Some Drugs Riskier than Others?

Samantha C. Shapiro, MD  |  February 4, 2025

Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis

Reproductive Health, Biosimilars & More in Focus at SOTA 2025

Ruth Jessen Hickman, MD  |  January 30, 2025

Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.

Filed under:Biologics/DMARDsConditionsEducation & TrainingGuidanceMeeting ReportsOther ACR meetings Tagged with:ACR State-of-the-Art Clinical SymposiumBiosimilarsIgG4 related diseaseLupusOsteoporosispregnancypregnancy complicationspregnant womenskinState-of-the-Art Clinical Symposium

Answering the Call: Anisha Dua, MD, MPH, Looks Ahead to New Role on Committee on Training

Carina Stanton  |  January 29, 2025

Building on her experiences in her practice and through the ACR, this rheumatology leader and educator is eager to advance the work of the COT.

Filed under:Career DevelopmentEducation & TrainingProfiles Tagged with:ACR Committee on Trainingeducation and training

Federally Funded Providers Must Provide Language Assistance Services by July 5

From the College  |  January 6, 2025

By July 5, all providers who participate in federally funded healthcare programs, including Medicare and Medicaid, must provide language assistance programs for patients to meet requirements of Section 1557 of the Affordable Care Act.

Filed under:Legal UpdatesPractice Support Tagged with:Access to careAffordable Care Act (ACA)

ARP Celebrates 58 Years of Achievements & Transformations, Identifies Challenges

Thomas R. Collins  |  December 27, 2024

ACR Convergence 2024—In a wide-ranging and engaging discussion, members of the Association of Rheumatology Professionals (ARP) tracked their progress over the years across clinical practice, research production and representation in the field, while outlining challenges and opportunities to come. The session at ACR Convergence included a panel and an audience full of past presidents of…

Filed under:ACR ConvergenceMeeting ReportsMeeting Reports Tagged with:Association of Rheumatology Professionals (ARP)

Retroperitoneal Fibrosis & IgG4-Related Disease

Mithu Maheswaranathan, MD  |  December 11, 2024

WASHINGTON, D.C.—Retroperitoneal fibrosis (RPF) is often a challenging diagnosis to make, given a lack of serologic biomarkers and often difficulty in accessing tissue for biopsy, especially in cases confined to the retroperitoneum. The topic of retroperitoneal fibrosis was discussed during the CARE to Test Your Knowledge: Retroperitoneal Fibrosis session at ACR Convergence 2024. John Stone,…

Filed under:ACR ConvergenceConditionsOther Rheumatic Conditions Tagged with:ACR Convergence 2024IgG4 related diseaseIgG4-RDretroperitoneal fibrosis

The Ethical Tug-of-War Over Biosimilar Adoption

Karen Ferguson, MS, & Richard L. Allman, MD, MS, FACP, FACR  |  December 9, 2024

The advent of biosimilar medications has offered the promise of significant cost savings for healthcare systems and patients. Biosimilars are highly similar versions of existing biologic drugs, providing a more affordable alternative once the original biologic patent expires. However, the adoption of biosimilars in the U.S. has been hampered by myriad roadblocks, many of which…

Filed under:Biologics/DMARDsDrug UpdatesEthicsGuidance Tagged with:BiosimilarsEthics ForumMedical necessitypharmacy benefit managers (PBMs)

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Key Research in Axial Spondyloarthritis Encapsulated

David S. Pisetsky, MD, PhD  |  December 2, 2024

Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize the abstracts and comment on why each is important, addressing the relevance for clinicians and the potential impact on future research.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsGuidanceMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 axSpA

Considerations for Lung Transplants in Patients with SARD-ILD

Ruth Jessen Hickman, MD  |  December 2, 2024

At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024ILDinterstitial lung disease (ILD)lung transplantlungsorgan transplantSARD-ILDsystemic autoimmune rheumatic disease-related interstitial lung disease

  • « Previous Page
  • 1
  • …
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences